NCT01107743
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
See it on ClinicalTrials.gov ↗1,245 people
63.2%
36.8%
787 womenmiddle line = equal numbers458 men
- Phase
- —
- Paid for by
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Finished
- 2012-04
- Health conditions
- Hypertension, Angina Pectoris, Hypercholesterolemia, Familial Hypercholesterolemia
- Who could join
- Anyone
- Ages
- no minimum – no maximum
- Average age
- Not reported
- Age 65+
- 69.7%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Some results split by sex
- Race
- Not reported
Women left out
No rules that kept women out were found.
Study titles and rules are shown in their original English.